Abstract:

Objective To investigate the clinical value of combined determination of serum tumor maker Golgi protein 73（GP73）and alpha-fetoprotein （AFP） in the diagnosis of hepatocellular carcinoma（HCC）. Methods Serums of 30 HCC patients， 30 liver cirrhosis and 20 healthy controls were collected from Feb. 2011 to Jan. 2012. Serum GP73 and AFP levels were determined by ELISA method and ECLLA method respectively. Results Serum GP73 levels in the HCC，liver cirrhosis and healthy groups were （251.9±130.2）ng／ml，（74.7±40.6）ng／ml and（12.2±4.0）ng／ml respectively， and AFP were （141.6±158.3）ng／ml，（36.0±35.0）ng／ml and （2.2±1.5）ng／ml respectively. Serum GP73 and AFP levels in HCC group were higher than those of non-HCC groups（P＜0.05）. The sensitivity of GP73 in detection was 76.7％，specificity was 82.0％， Youden index was 58.7％ and total matching ratio was 80.0％. The sensitivity of AFP was 63.3％， specificity was 80.0％， Youden index was 43.3％ and total matching ratio was 68.8％. Combined detection of the two parameters could improve the sensitivity up to 86.7％ and Youden index to 64.7％ and total matching ratio to 81.3％，then maintain a high specificity of 78.0％. Conclusion GP73 and AFP are highly expressed in the serum of the patients with HCC. Combined determination of serum GP73 and AFP can improve HCC diagnostic performance.